Withdrawn (DGU 2026) - Oct 15, 2026 - Abstract #TiP-09; Pres time: Sep 17, 2026; 08:00 AM - 09:30 AM; Location: Foyer in front of room 4; P3 | "In Part 1 (dose selection), randomization will be 1:1:1 to BMS-986365 400 or 300 mg BID or investigator's choice: enzalutamide 160 mg QD, abiraterone 1000 mg QD + prednisone/prednisolone 5 mg BID, or docetaxel 75 mg/m² Q3W (≤10 cycles) + prednisone/prednisolone 5 mg BID. ~275 sites (14 in Germany) across 26 countries in North America, Europe, South America & East Asia. Initiated March 2025; primary completion expected September 2027."
Castration-Resistant Prostate Cancer • Prostate Cancer
|
|
B. Hadashik 1; K. Nguyen Chi 2; RR McKay 3; SK Sandhu 4; JA Arranz 5; P. Barthelemy 6; N. Matsubara 7; ND Shore 8; D.Ye 9; T. Cascella 10; I. Irincheeva 10; S. Kreiser 11; A. Thiery-Vuillemin 10; DE Rathkopf 12
|